The role of angiotensin converting enzyme genotype in coronary artery ectasia

Huseyin Uyarel1, Ertan Okmen, Zeynep Tartan

  • 1Department of Cardiology, Siyami Ersek Cardiovascular and Thoracic Surgery Center, Istanbul, Turkey.

Insights

The angiotensin converting enzyme (ACE) DD genotype may increase the risk of developing coronary artery ectasia (CAE), a condition characterized by coronary artery dilation. Further research is needed to confirm this association.

Area of Science:

  • Cardiology
  • Genetics
  • Vascular Biology

Background:

  • Coronary artery ectasia (CAE) involves abnormal coronary artery dilation, often linked to atherosclerosis.
  • The exact causes of CAE and why only some individuals develop it remain unclear.
  • The renin-angiotensin system and matrix metalloproteinases are implicated in CAE pathogenesis.

Purpose of the Study:

  • To investigate the potential role of angiotensin converting enzyme (ACE) gene polymorphism in the development of coronary artery ectasia (CAE).
  • To determine if specific ACE genotypes are associated with an increased risk of CAE.

Main Methods:

  • Retrospective analysis of 112 patients undergoing coronary angiography.
  • Categorization into two groups: 56 patients with CAE and 56 with significant coronary artery disease but no CAE.
  • Determination of ACE insertion/deletion (ID) genotype using Polymerase Chain Reaction (PCR).

Main Results:

  • The DD genotype of the ACE gene was found more frequently in patients with CAE (39%) compared to those without CAE (18%) (P < 0.05).
  • The presence of the I allele was higher in patients without CAE (82.1%) than in those with CAE (60.7%) (P < 0.05).

Conclusions:

  • The ACE DD genotype may represent a genetic risk factor contributing to the development of coronary artery ectasia.
  • These findings suggest a potential link between ACE gene variations and the pathogenesis of CAE.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...